STAT3 and neoplasm: Although promising for disrupting tumor proliferation and immune evasion, STAT3 and JAK inhibitors face significant limitations due to poor BBB penetration.279 Overcoming these obstacles requires innovative drug delivery approaches, such as nanoparticle-based carriers and convection-enhanced delivery, to enhance the therapeutic reach.